Axsome Therapeutics Q1 2024 GAAP EPS $(1.44) Misses $(1.21) Estimate, Sales $74.999M Beat $73.295M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics reported Q1 2024 earnings with a GAAP EPS of $(1.44), missing the $(1.21) estimate, but sales of $74.999M exceeded the $73.295M forecast. This represents a 20.70% decrease in sales compared to the same period last year.
May 06, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Axsome Therapeutics missed EPS estimates but beat sales forecasts for Q1 2024, with a significant decrease in sales compared to last year.
Missing the EPS estimate by 19.01% is likely to negatively impact investor sentiment and stock price in the short term. However, beating sales estimates might offset some of the negative impact. The significant year-over-year decrease in sales by 20.70% further contributes to the negative outlook, indicating potential challenges in revenue growth or market conditions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100